First FDA-Approved Recombinant von Willebrand Factor, Vonvendi, Now Available for von Willebrand Disease
The following is excerpted from a press release from Baxalta, now a part of Shire. Read the press release in it's entirety here.
Shire has announced that Vonvendi [von Willebrand factor (Recombinant)], indicated for the on-demand treatment and control of bleeding episodes in adults (age 18 and older) diagnosed with von Willebrand disease, is now available from Shire’s Hematology Support Center (HSC) through a patient service model.
Patients interested in Vonvendi should speak with their healthcare provider to determine if Vonvendi is right for them. Starting on Vonvendi will require a healthcare provider to enroll the patient in an Activation Program. To learn more about the drug, visit http://www.vonvendi.com.
Assisting and Advocating for the Bleeding Disorders Community